Forcefield Therapeutics
UK - LondonBiotechnology
Focus: Forcefield Therapeutics is a UK-based public biotech company focused on cardiomyocyte protective drugs for metabolic diseases. The company operates at a modest scale with limited visible pipeline disclosure.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
3
Should You Work at Forcefield Therapeutics?
AI assessmentConsider Forcefield only if you have deep interest in cardiometabolic biology and can tolerate early-stage risk and limited transparency.
Why Work Here
- Specialized focus on cardiomyocyte protection in metabolic disease offers deep therapeutic expertise for candidates seeking niche domain knowledge.
- Public company status provides regulatory transparency and equity upside potential for early-stage contributors.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Forcefield Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.